Crossmark

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

Crossref DOI link: https://doi.org/10.1186/s40164-018-0110-0

Published Online: 2018-08-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gregersen, Henrik https://orcid.org/0000-0001-6632-5308
Do, Trung

Kristensen, Ida Bruun

Frølund, Ulf Christian

Andersen, Niels Frost

Nielsen, Lene Kongsgaard

Andersen, Christen Lykkegaard

Klausen, Tobias Wirenfeldt

Vangsted, Annette Juul

Abildgaard, Niels
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02573935 at ClinicalTrials.gov

Documents that mention this clinical trial

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
https://doi.org/10.1186/s40164-018-0110-0
Funding

Funding for this research was provided by:

The Obel Family Foundation

The Karen Elise Jensen Foundation

Danish Myeloma Study Group
License Information

Text and Data Mining valid from 2018-08-13

Version of Record valid from 2018-08-13
More Information

Article History

Received: 9 June 2018

Accepted: 6 August 2018

First Online: 13 August 2018

Document is current

Any future updates will be listed below